$CELC
Celcuity Inc.

2024 Q4 Form 10-Q Financial Statement

#000149315224046022 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.472M
YoY Change 75.35%
% of Gross Profit
Research & Development $27.59M
YoY Change 57.75%
% of Gross Profit
Depreciation & Amortization $34.02K
YoY Change 13.4%
% of Gross Profit
Operating Expenses $30.06M
YoY Change 59.06%
Operating Profit -$30.06M
YoY Change 59.06%
Interest Expense $3.344M
YoY Change 143.71%
% of Operating Profit
Other Income/Expense, Net $268.1K
YoY Change -45.67%
Pretax Income -$29.79M
YoY Change 61.87%
Income Tax
% Of Pretax Income
Net Earnings -$29.79M
YoY Change 61.87%
Net Earnings / Revenue
Basic Earnings Per Share -$0.70
Diluted Earnings Per Share -$0.70
COMMON SHARES
Basic Shares Outstanding 37.13M shares 37.03M shares
Diluted Shares Outstanding 42.79M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $264.1M
YoY Change 97.21%
Cash & Equivalents $12.60M
Short-Term Investments $251.5M
Other Short-Term Assets $8.380M
YoY Change 7.43%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $272.4M
YoY Change 92.25%
LONG-TERM ASSETS
Property, Plant & Equipment $338.8K
YoY Change 51.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $598.5K
YoY Change -11.03%
TOTAL ASSETS
Total Short-Term Assets $272.4M
Total Long-Term Assets $598.5K
Total Assets $273.0M
YoY Change 91.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.159M
YoY Change 62.54%
Accrued Expenses $16.97M
YoY Change 146.47%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $26.31M
YoY Change 106.99%
LONG-TERM LIABILITIES
Long-Term Debt $96.92M
YoY Change 165.54%
Other Long-Term Liabilities $95.70K
YoY Change -68.1%
Total Long-Term Liabilities $97.02M
YoY Change 163.64%
TOTAL LIABILITIES
Total Short-Term Liabilities $26.31M
Total Long-Term Liabilities $97.02M
Total Liabilities $123.3M
YoY Change 149.21%
SHAREHOLDERS EQUITY
Retained Earnings -$235.2M
YoY Change 66.54%
Common Stock $37.12K
YoY Change 65.93%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $149.7M
YoY Change
Total Liabilities & Shareholders Equity $273.0M
YoY Change 91.76%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$29.79M
YoY Change 61.87%
Depreciation, Depletion And Amortization $34.02K
YoY Change 13.4%
Cash From Operating Activities -$20.56M
YoY Change 61.27%
INVESTING ACTIVITIES
Capital Expenditures $50.78K
YoY Change 1.56%
Acquisitions
YoY Change
Other Investing Activities $1.954M
YoY Change -68.98%
Cash From Investing Activities $1.904M
YoY Change -69.54%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 802.6K
YoY Change 7926.0%
NET CHANGE
Cash From Operating Activities -20.56M
Cash From Investing Activities 1.904M
Cash From Financing Activities 802.6K
Net Change In Cash -17.86M
YoY Change 175.12%
FREE CASH FLOW
Cash From Operating Activities -$20.56M
Capital Expenditures $50.78K
Free Cash Flow -$20.61M
YoY Change 61.03%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
us-gaap Operating Income Loss
OperatingIncomeLoss
-46501059 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
133736664 usd
CY2024Q2 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
1410513 usd
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
65000000 shares
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30662774 usd
CY2024Q3 us-gaap Short Term Investments
ShortTermInvestments
251455468 usd
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
149919974 usd
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
8379682 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
10007849 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
272438439 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
190590597 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
338787 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
228782 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
259744 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
400019 usd
CY2024Q3 us-gaap Assets
Assets
273036970 usd
CY2023Q4 us-gaap Assets
Assets
191219398 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
9158778 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5076699 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
175226 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
184950 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16974725 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8927094 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
26308729 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14188743 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
95699 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
225922 usd
CY2024Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
96923914 usd
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
37035411 usd
CY2024Q3 us-gaap Liabilities
Liabilities
123328342 usd
CY2023Q4 us-gaap Liabilities
Liabilities
51450076 usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000 shares
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
317577 shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
317577 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
854134 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
854134 shares
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
854 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
65000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37116267 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37116267 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25506012 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
37116 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
25506 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
384873261 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
299818965 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-160076003 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
149708628 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
273036970 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
191219398 usd
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2024Q1 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
usd
CY2024Q2 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
usd
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
CELCUITY INC.
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-2863566
dei Entity Address Address Line1
EntityAddressAddressLine1
16305 36th
dei Entity Address Address Line3
EntityAddressAddressLine3
Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
Minneapolis
dei Entity Address State Or Province
EntityAddressStateOrProvince
MN
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
55446
dei City Area Code
CityAreaCode
(763)
dei Trading Symbol
TradingSymbol
CELC
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Shell Company
EntityShellCompany
false
dei Entity Listing Par Value Per Share
EntityListingParValuePerShare
0.001
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12603289 usd
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
65000000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25506012 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
139769322 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27587483 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17488236 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
70732017 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
42512811 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2472416 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1409801 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6104803 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3988248 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
30059899 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
18898037 usd
us-gaap Operating Expenses
OperatingExpenses
76836820 usd
us-gaap Operating Expenses
OperatingExpenses
46501059 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-30059899 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-18898037 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-76836820 usd
CY2024Q3 us-gaap Interest Expense
InterestExpense
3343989 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
1372132 usd
us-gaap Interest Expense
InterestExpense
7005284 usd
us-gaap Interest Expense
InterestExpense
3929140 usd
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
3612099 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1865629 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
8716040 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
5499555 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
268110 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
493497 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1710756 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1570415 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-29791789 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18404540 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-75126064 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-44930644 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-18404540 usd
us-gaap Net Income Loss
NetIncomeLoss
-75126064 usd
us-gaap Net Income Loss
NetIncomeLoss
-44930644 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.70
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.70
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.83
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.83
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.96
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.96
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.05
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.05
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42793047 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42793047 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22117626 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38299548 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38299548 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21920147 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21920147 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
139769322 usd
CY2024Q1 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
1331346 usd
CY2024Q1 CELC Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
14009151 usd
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
239300 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-21612455 usd
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
131246 usd
CY2024Q2 CELC Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
172986 usd
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
95711 usd
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7642200 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
263727 usd
CY2024Q2 CELC Stock Issued During Period Value Issuance Upon Closing Of Followon Offering Net Of Underwriting Discounts And Offering Costs
StockIssuedDuringPeriodValueIssuanceUponClosingOfFollowonOfferingNetOfUnderwritingDiscountsAndOfferingCosts
56252108 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1228911 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-23721820 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
176684792 usd
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
330744 usd
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001603454
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
usd
CY2023Q2 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
usd
CY2023Q3 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
usd
us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
usd
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
usd
CELC Proceeds From Atm Offering Net Of Issuance Costs
ProceedsFromAtmOfferingNetOfIssuanceCosts
usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
usd
CELC Common Stock Warrants Issued With Note Payable Transaction
CommonStockWarrantsIssuedWithNotePayableTransaction
usd
CY2024Q3 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
usd
CY2023Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
usd
CY2023Q4 CELC Final Fee
FinalFee
usd
dei Document Type
DocumentType
10-Q
dei Entity File Number
EntityFileNumber
001-38207
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Address Address Line2
EntityAddressAddressLine2
Avenue North
dei Local Phone Number
LocalPhoneNumber
392-0767
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37129556 shares
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
318 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-235202067 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-29791789 usd
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22117626 shares
CY2024Q3 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
1931201 usd
CY2024Q3 CELC Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
553680 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-29791789 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
149708628 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
133771467 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
1273282 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
127922 usd
CY2023Q1 CELC Adjustments To Additional Paid In Capital Stock Issued Issuance Costs Issuance With Private Placement Offering
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsIssuanceWithPrivatePlacementOffering
7486 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-11938417 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
123226768 usd
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
1276982 usd
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
102638 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
113640 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-14587687 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
110132341 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
110132341 usd
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
1108637 usd
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
60002 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-18404540 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
92896440 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
92896440 usd
us-gaap Net Income Loss
NetIncomeLoss
-75126064 usd
us-gaap Net Income Loss
NetIncomeLoss
-44930644 usd
us-gaap Depreciation
Depreciation
94693 usd
us-gaap Depreciation
Depreciation
114824 usd
us-gaap Share Based Compensation
ShareBasedCompensation
4673059 usd
us-gaap Share Based Compensation
ShareBasedCompensation
3658902 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
780555 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
177939 usd
us-gaap Paid In Kind Interest
PaidInKindInterest
1110584 usd
us-gaap Paid In Kind Interest
PaidInKindInterest
1345760 usd
CELC Noncash Operating Lease Expense Net
NoncashOperatingLeaseExpenseNet
326 usd
CELC Noncash Operating Lease Expense Net
NoncashOperatingLeaseExpenseNet
3171 usd
CELC Change In Accrued Interest Income
ChangeInAccruedInterestIncome
1112420 usd
CELC Change In Accrued Interest Income
ChangeInAccruedInterestIncome
439331 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-1740973 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
1065732 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4093903 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3031923 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
8047631 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2826856 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-55696760 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-35276332 usd
us-gaap Proceeds From Sale And Maturity Of Other Investments
ProceedsFromSaleAndMaturityOfOtherInvestments
415134729 usd
us-gaap Proceeds From Sale And Maturity Of Other Investments
ProceedsFromSaleAndMaturityOfOtherInvestments
221054402 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
515557800 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
184779534 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
204729 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
64945 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-100627800 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
36209923 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
14735816 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
665758 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
285564 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
131246 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
102638 usd
us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
56252109 usd
CY2024Q3 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
2437644 usd
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
59226276 usd
CELC Proceeds From Atm Offering Net Of Issuance Costs
ProceedsFromAtmOfferingNetOfIssuanceCosts
7356107 usd
CELC Payments For Secondary Registration Statement Costs
PaymentsForSecondaryRegistrationStatementCosts
102237 usd
CELC Payments For Secondary Registration Statement Costs
PaymentsForSecondaryRegistrationStatementCosts
128298 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
2716 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
2449 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
138265075 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
254739 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-18059485 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1188330 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
30662774 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24571557 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12603289 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
25759887 usd
us-gaap Interest Paid Net
InterestPaidNet
5114145 usd
us-gaap Interest Paid Net
InterestPaidNet
2405441 usd
CELC Offering And Registration Statement Costs Included In Accounts Payable
OfferingAndRegistrationStatementCostsIncludedInAccountsPayable
44621 usd
CELC Offering And Registration Statement Costs Included In Accounts Payable
OfferingAndRegistrationStatementCostsIncludedInAccountsPayable
13865 usd
CELC Property And Equipment Included In Accounts Payable
PropertyAndEquipmentIncludedInAccountsPayable
13584 usd
CELC Property And Equipment Included In Accounts Payable
PropertyAndEquipmentIncludedInAccountsPayable
12961 usd
CELC Common Stock Warrants Issued With Note Payable Transaction
CommonStockWarrantsIssuedWithNotePayableTransaction
1228911 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84F_eus-gaap--UseOfEstimates_zrTllmy54zV2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_86B_zbKE3z46oc2">Accounting Estimates</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management uses estimates and assumptions in preparing these unaudited condensed financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could differ from those estimates and the difference could be material. Significant items subject to such estimates and assumptions include the valuation of stock-based compensation and prepaid or accrued clinical trial costs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zi4BawkjulIf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_867_zcYniNWVo2fj">Risks and Uncertainties</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to risks common to companies in the development stage including, but not limited to, the clinical and commercial success of its initial drug product, gedatolisib, the regulatory approval of gedatolisib, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and consumers, and significant competition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12910103 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20579419 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12910103 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20579419 shares
CY2024Q3 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
251455468 usd
CY2024Q3 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
196920 usd
CY2024Q3 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
251652388 usd
CY2023Q4 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
149919974 usd
CY2023Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
30995 usd
CY2023Q4 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
149950969 usd
CY2024Q3 us-gaap Contractual Obligation
ContractualObligation
1600000 usd
CY2024Q3 us-gaap Other Commitment
OtherCommitment
200000 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25506012 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000 shares
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
854134 shares
CY2024Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1739080 shares
CY2024Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
8.05
CY2024Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
14000000.0 usd
CY2024Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
3683 shares
CY2024Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
19390 shares
CY2024Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
65204 shares
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
65000000 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37116267 shares
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000 shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
317577 shares
us-gaap Dividends
Dividends
0 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0348 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0471 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0341 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0461 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.712 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7610 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.780 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.798 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2024Q3 CELC Employee Service Share Based Compensation Non Vested Awards Compensation Cost To Be Recognized Remainder Of Fiscal Year
EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedRemainderOfFiscalYear
2158997 usd
CY2024Q3 CELC Employee Service Sharebased Compensation Nonvested Awards Compensation Cost To Be Recognized Next Twelve Months
EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedNextTwelveMonths
7470910 usd
CY2024Q3 CELC Employee Service Share Based Compensation Non Vested Awards Compensation Cost To Be Recognized Within Two Year
EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinTwoYear
6066260 usd
CY2024Q3 CELC Employee Service Sharebased Compensation Nonvested Awards Compensation Cost To Be Recognizedwithin Three Years
EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostToBeRecognizedwithinThreeYears
4918768 usd
CY2024Q3 CELC Employee Service Share Based Compensation Non Vested Awards Compensation Cost To Be Recognized Within Four Years
EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostToBeRecognizedWithinFourYears
1740835 usd
CY2024Q3 CELC Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost To Be Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostToBeRecognized
22355770 usd
CY2024Q3 us-gaap Share Based Compensation
ShareBasedCompensation
1931201 usd
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
1108637 usd
us-gaap Share Based Compensation
ShareBasedCompensation
4673059 usd
us-gaap Share Based Compensation
ShareBasedCompensation
3658902 usd
CY2024Q3 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
100000000 usd
CY2023Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
35000000 usd
CY2024Q3 CELC Final Fee
FinalFee
4500000 usd
CY2024Q3 CELC Payment In Kind Interest Debt
PaymentInKindInterestDebt
340164 usd
CY2023Q4 CELC Payment In Kind Interest Debt
PaymentInKindInterestDebt
2565660 usd
CY2024Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
1856880 usd
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
480810 usd
CY2024Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
6059370 usd
CY2023Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
49439 usd
CY2024Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
96923914 usd
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
37035411 usd
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
30538311 usd
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
52351390 usd
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
21950463 usd
CY2024Q3 us-gaap Long Term Debt
LongTermDebt
104840164 usd
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001493152-24-046022-index-headers.html Edgar Link pending
0001493152-24-046022-index.html Edgar Link pending
0001493152-24-046022.txt Edgar Link pending
0001493152-24-046022-xbrl.zip Edgar Link pending
celc-20240930.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
celc-20240930_def.xml Edgar Link unprocessable
celc-20240930_lab.xml Edgar Link unprocessable
celc-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
celc-20240930_cal.xml Edgar Link unprocessable